Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms

Shinichi Takahashi, Miho Ushida, Risa Komine, Aya Shimodaira, Toshihiro Uchida, Hiroaki Ishihara, Toshiro Shibano, Gentaro Watanabe, Yasuo Ikeda, Mitsuru Murata

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aspirin's inhibitory effect on platelet function has been shown to be highly heterogeneous. However, due to the considerable individual variation in pharmacokinetics after aspirin intake, it has been difficult to investigate the mechanism of aspirin resistance empirically. Our objective was to examine whether platelet responsiveness to in vitro aspirin treatment could be affected by cyclooxygenase (COX)-1/2 protein levels in platelets or single-nucleotide polymorphisms (SNPs), which could possibly change specific activity of enzymes and/or aspirin susceptibility. Collagen/epinephrine closure time (CEPI-CT) of PFA-100 in blood from 178 healthy males was assessed with/without aspirin. Platelet COX-1 protein levels and the sequences of COX-1 gene exons were examined in three groups categorized by CEPI-CT: PR (Poor responders to aspirin), 10 people showing the shortest CEPI-CT under aspirin; GR-High or GR-Low (good responders to aspirin with high or low platelet basal reactivity), 10 people showing CEPI-CT over 300 s under aspirin and having the shortest or longest basal CEPI-CT, respectively. We analyzed the three groups, representing phenotypic extremes, aiming to increase statistical power to investigate the possible relevance of COXs to platelet response to aspirin. Western blot analysis revealed that COX-1 was abundantly expressed in platelets at comparable levels among the three groups, whereas COX-2 was undetectable. The frequencies of nonsynonymous COX-1/2 SNPs were unlikely to explain the difference in aspirin responsiveness considering the observed genotype frequencies and wide individual variation in platelet response. These results suggest that heterogeneity in platelet responsiveness to in vitro aspirin is independent of COX-1/2 protein levels and SNPs.

Original languageEnglish
Pages (from-to)509-517
Number of pages9
JournalThrombosis Research
Volume121
Issue number4
DOIs
Publication statusPublished - 2008

Fingerprint

Cyclooxygenase 1
Cyclooxygenase 2
Aspirin
Blood Platelets
Proteins
Epinephrine
Collagen
Single Nucleotide Polymorphism
In Vitro Techniques
Exons

Keywords

  • Aspirin resistance
  • COX-1 protein
  • PFA-100
  • SNPs

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. / Takahashi, Shinichi; Ushida, Miho; Komine, Risa; Shimodaira, Aya; Uchida, Toshihiro; Ishihara, Hiroaki; Shibano, Toshiro; Watanabe, Gentaro; Ikeda, Yasuo; Murata, Mitsuru.

In: Thrombosis Research, Vol. 121, No. 4, 2008, p. 509-517.

Research output: Contribution to journalArticle

Takahashi, S, Ushida, M, Komine, R, Shimodaira, A, Uchida, T, Ishihara, H, Shibano, T, Watanabe, G, Ikeda, Y & Murata, M 2008, 'Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms', Thrombosis Research, vol. 121, no. 4, pp. 509-517. https://doi.org/10.1016/j.thromres.2007.05.017
Takahashi, Shinichi ; Ushida, Miho ; Komine, Risa ; Shimodaira, Aya ; Uchida, Toshihiro ; Ishihara, Hiroaki ; Shibano, Toshiro ; Watanabe, Gentaro ; Ikeda, Yasuo ; Murata, Mitsuru. / Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. In: Thrombosis Research. 2008 ; Vol. 121, No. 4. pp. 509-517.
@article{e20f142e463d419e8c519c5f4e97d811,
title = "Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms",
abstract = "Aspirin's inhibitory effect on platelet function has been shown to be highly heterogeneous. However, due to the considerable individual variation in pharmacokinetics after aspirin intake, it has been difficult to investigate the mechanism of aspirin resistance empirically. Our objective was to examine whether platelet responsiveness to in vitro aspirin treatment could be affected by cyclooxygenase (COX)-1/2 protein levels in platelets or single-nucleotide polymorphisms (SNPs), which could possibly change specific activity of enzymes and/or aspirin susceptibility. Collagen/epinephrine closure time (CEPI-CT) of PFA-100 in blood from 178 healthy males was assessed with/without aspirin. Platelet COX-1 protein levels and the sequences of COX-1 gene exons were examined in three groups categorized by CEPI-CT: PR (Poor responders to aspirin), 10 people showing the shortest CEPI-CT under aspirin; GR-High or GR-Low (good responders to aspirin with high or low platelet basal reactivity), 10 people showing CEPI-CT over 300 s under aspirin and having the shortest or longest basal CEPI-CT, respectively. We analyzed the three groups, representing phenotypic extremes, aiming to increase statistical power to investigate the possible relevance of COXs to platelet response to aspirin. Western blot analysis revealed that COX-1 was abundantly expressed in platelets at comparable levels among the three groups, whereas COX-2 was undetectable. The frequencies of nonsynonymous COX-1/2 SNPs were unlikely to explain the difference in aspirin responsiveness considering the observed genotype frequencies and wide individual variation in platelet response. These results suggest that heterogeneity in platelet responsiveness to in vitro aspirin is independent of COX-1/2 protein levels and SNPs.",
keywords = "Aspirin resistance, COX-1 protein, PFA-100, SNPs",
author = "Shinichi Takahashi and Miho Ushida and Risa Komine and Aya Shimodaira and Toshihiro Uchida and Hiroaki Ishihara and Toshiro Shibano and Gentaro Watanabe and Yasuo Ikeda and Mitsuru Murata",
year = "2008",
doi = "10.1016/j.thromres.2007.05.017",
language = "English",
volume = "121",
pages = "509--517",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms

AU - Takahashi, Shinichi

AU - Ushida, Miho

AU - Komine, Risa

AU - Shimodaira, Aya

AU - Uchida, Toshihiro

AU - Ishihara, Hiroaki

AU - Shibano, Toshiro

AU - Watanabe, Gentaro

AU - Ikeda, Yasuo

AU - Murata, Mitsuru

PY - 2008

Y1 - 2008

N2 - Aspirin's inhibitory effect on platelet function has been shown to be highly heterogeneous. However, due to the considerable individual variation in pharmacokinetics after aspirin intake, it has been difficult to investigate the mechanism of aspirin resistance empirically. Our objective was to examine whether platelet responsiveness to in vitro aspirin treatment could be affected by cyclooxygenase (COX)-1/2 protein levels in platelets or single-nucleotide polymorphisms (SNPs), which could possibly change specific activity of enzymes and/or aspirin susceptibility. Collagen/epinephrine closure time (CEPI-CT) of PFA-100 in blood from 178 healthy males was assessed with/without aspirin. Platelet COX-1 protein levels and the sequences of COX-1 gene exons were examined in three groups categorized by CEPI-CT: PR (Poor responders to aspirin), 10 people showing the shortest CEPI-CT under aspirin; GR-High or GR-Low (good responders to aspirin with high or low platelet basal reactivity), 10 people showing CEPI-CT over 300 s under aspirin and having the shortest or longest basal CEPI-CT, respectively. We analyzed the three groups, representing phenotypic extremes, aiming to increase statistical power to investigate the possible relevance of COXs to platelet response to aspirin. Western blot analysis revealed that COX-1 was abundantly expressed in platelets at comparable levels among the three groups, whereas COX-2 was undetectable. The frequencies of nonsynonymous COX-1/2 SNPs were unlikely to explain the difference in aspirin responsiveness considering the observed genotype frequencies and wide individual variation in platelet response. These results suggest that heterogeneity in platelet responsiveness to in vitro aspirin is independent of COX-1/2 protein levels and SNPs.

AB - Aspirin's inhibitory effect on platelet function has been shown to be highly heterogeneous. However, due to the considerable individual variation in pharmacokinetics after aspirin intake, it has been difficult to investigate the mechanism of aspirin resistance empirically. Our objective was to examine whether platelet responsiveness to in vitro aspirin treatment could be affected by cyclooxygenase (COX)-1/2 protein levels in platelets or single-nucleotide polymorphisms (SNPs), which could possibly change specific activity of enzymes and/or aspirin susceptibility. Collagen/epinephrine closure time (CEPI-CT) of PFA-100 in blood from 178 healthy males was assessed with/without aspirin. Platelet COX-1 protein levels and the sequences of COX-1 gene exons were examined in three groups categorized by CEPI-CT: PR (Poor responders to aspirin), 10 people showing the shortest CEPI-CT under aspirin; GR-High or GR-Low (good responders to aspirin with high or low platelet basal reactivity), 10 people showing CEPI-CT over 300 s under aspirin and having the shortest or longest basal CEPI-CT, respectively. We analyzed the three groups, representing phenotypic extremes, aiming to increase statistical power to investigate the possible relevance of COXs to platelet response to aspirin. Western blot analysis revealed that COX-1 was abundantly expressed in platelets at comparable levels among the three groups, whereas COX-2 was undetectable. The frequencies of nonsynonymous COX-1/2 SNPs were unlikely to explain the difference in aspirin responsiveness considering the observed genotype frequencies and wide individual variation in platelet response. These results suggest that heterogeneity in platelet responsiveness to in vitro aspirin is independent of COX-1/2 protein levels and SNPs.

KW - Aspirin resistance

KW - COX-1 protein

KW - PFA-100

KW - SNPs

UR - http://www.scopus.com/inward/record.url?scp=38649098154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649098154&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2007.05.017

DO - 10.1016/j.thromres.2007.05.017

M3 - Article

C2 - 17631383

AN - SCOPUS:38649098154

VL - 121

SP - 509

EP - 517

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 4

ER -